245 related articles for article (PubMed ID: 37255740)
1. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
4. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept: First Approval.
Markham A
Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
[TBL] [Abstract][Full Text] [Related]
6. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
7. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
Musallam KM; Rivella S; Taher AT
Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
[No Abstract] [Full Text] [Related]
8. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
9. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
[TBL] [Abstract][Full Text] [Related]
10. Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).
Alashkar F; Klump H; Lange CP; Proske P; Schüssler M; Yamamoto R; Carpinteiro A; Berliner CA; Schlosser TW; Röth A; Reinhardt HC
Eur J Haematol; 2022 Dec; 109(6):664-671. PubMed ID: 36045599
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD; Taher AT; Piga A; Shah F; Voskaridou E; Viprakasit V; Porter JB; Hermine O; Neufeld EJ; Thompson AA; Tang D; Yucel A; Lord-Bessen J; Yu P; Guo S; Shetty JK; Miteva D; Zinger T; Backstrom JT; Oliva EN
Eur J Haematol; 2023 Jul; 111(1):113-124. PubMed ID: 37095595
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
13. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
14. Luspatercept to treat β-thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2020 Jul; 56(7):447-458. PubMed ID: 32648855
[TBL] [Abstract][Full Text] [Related]
15. Luspatercept for β-thalassemia: beyond red blood cell transfusions.
Taher AT; Cappellini MD
Expert Opin Biol Ther; 2021 Nov; 21(11):1363-1371. PubMed ID: 34404288
[TBL] [Abstract][Full Text] [Related]
16. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
[TBL] [Abstract][Full Text] [Related]
17. Luspatercept's use in a patient with transfusion-dependent beta-thalassemia and intrathoracic extramedullary hematopoiesis (EMH).
Seijari MN; Alshurafa A; Yassin MA
Clin Case Rep; 2024 May; 12(5):e8795. PubMed ID: 38736568
[TBL] [Abstract][Full Text] [Related]
18. The use of luspatercept for thalassemia in adults.
Cappellini MD; Taher AT
Blood Adv; 2021 Jan; 5(1):326-333. PubMed ID: 33570654
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.
Darvishi-Khezri H; Karami H
Adv Ther; 2021 Apr; 38(4):1732-1745. PubMed ID: 33661441
[TBL] [Abstract][Full Text] [Related]
20. How I treat non-transfusion-dependent β-thalassemia.
Saliba AN; Musallam KM; Taher AT
Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]